ZIVO Bioscience, Inc. (ZIVO)
OTCMKTS
· Delayed Price · Currency is USD
17.10
0.00 (0.00%)
Mar 28, 2025, 4:00 PM EST
ZIVO Bioscience Revenue
In the year 2024, ZIVO Bioscience had annual revenue of $157.22K with 468.61% growth. ZIVO Bioscience had revenue of $90.00K in the quarter ending December 31, 2024, with 662.71% growth.
Revenue
157.22K
Revenue Growth
+468.61%
P/S Ratio
n/a
Revenue / Employee
22.46K
Employees
8
Market Cap
64.28M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.76B |
SS Innovations International | 16.04M |
Veradigm | 588.02M |
Elite Pharmaceuticals | 70.00M |
Glass House Brands | 200.90M |
Northwest Biotherapeutics | 1.60M |
Silence Therapeutics | 43.26M |
American Oncology Network | 1.76B |
ZIVO Bioscience News
- 7 weeks ago - ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry - Business Wire
- 2 months ago - ZIVO Bioscience to Present at The Microcap Conference 2025 - Business Wire
- 3 months ago - ZIVO Bioscience Reports Progress with Coccidiosis Treatment Licensing Opportunities - Business Wire
- 3 months ago - ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza - Business Wire
- 7 months ago - Director and 10% Owner Christopher Maggiore Acquires 31,336 Shares of Zivo Bioscience Inc (ZIVO) - GuruFocus
- 7 months ago - ZIVO Reports Favorable Results from 42-Day Confirmatory Study of its Coccidiosis Treatment in Broiler Chickens - Business Wire
- 9 months ago - Major Global Animal Health Company Launches 42-Day Confirmatory Study with ZIVO Bioscience's Coccidiosis Treatment in Broiler Chickens - Business Wire
- 1 year ago - ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study - Business Wire